Protocol Ledger

NCT06109818 · Phase II · COMPLETED

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis

Interventional Phase II clinical trial protocol NCT06109818 sponsored by Beijing InnoCare Pharma Tech Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-01-04 Enrollment: 129 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06109818
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)129 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06109818
Protocol FieldVerified Registry Value
NCT IdentifierNCT06109818
Consolidated Lead SponsorBeijing InnoCare Pharma Tech Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment129 participants (ACTUAL)
Registered Start Date2024-01-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI